Terms: = Germ cell tumor AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Diagnosis
222 results:
1. REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
Picca A; Touat M; Belin L; Gourmelon C; Harlay V; Cuzzubbo S; Cohen-Jonathan Moyal E; Bronnimann C; Di Stefano AL; Laurent I; Lerond J; Carpentier C; Bielle F; Ducray F; Dehais C;
Eur J Cancer; 2024 May; 202():114034. PubMed ID: 38537315
[TBL] [Abstract] [Full Text] [Related]
2. tumor-infiltrating macrophage associated lncRNA signature in cutaneous melanoma: implications for diagnosis, prognosis, and immunotherapy.
Wan Q; Deng Y; Wei R; Ma K; Tang J; Deng YP
Aging (Albany NY); 2024 Mar; 16(5):4518-4540. PubMed ID: 38475660
[TBL] [Abstract] [Full Text] [Related]
3. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving pd-1 blockade therapy.
Shen L; Tan H; Nie J; Jiang Y; Nuerhashi G; Qi H; Cao F; Wen C; Chen S; Zhang T; Zheng W; Liu P; Liu Y; Huang T; Li D; Zhang X; Fan W
Cancer Immunol Immunother; 2024 Mar; 73(4):68. PubMed ID: 38430269
[TBL] [Abstract] [Full Text] [Related]
4. Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy.
Teixeira RJ; de Souza VG; Sorroche BP; Paes VG; Zambuzi-Roberto FA; Pereira CAD; Vazquez VL; Arantes LMRB
Melanoma Res; 2024 Jun; 34(3):234-240. PubMed ID: 38364053
[TBL] [Abstract] [Full Text] [Related]
5. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract] [Full Text] [Related]
6. A prediction model for response to immune checkpoint inhibition in advanced melanoma.
van Duin IAJ; Verheijden RJ; van Diest PJ; Blokx WAM; El-Sharouni MA; Verhoeff JJC; Leiner T; van den Eertwegh AJM; de Groot JWB; van Not OJ; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; van der Veldt AAM; Vreugdenhil G; Wouters MWJM; Stevense-den Boer MAM; Boers-Sonderen MJ; Kapiteijn E; Suijkerbuijk KPM; Elias SG
Int J Cancer; 2024 May; 154(10):1760-1771. PubMed ID: 38296842
[TBL] [Abstract] [Full Text] [Related]
7. Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor-induced CNS inflammation.
Bjursten S; Zhao Z; Al Remawi H; Studahl M; Pandita A; Simrén J; Zetterberg H; Lundell AC; Rudin A; Ny L; Levin M
EBioMedicine; 2024 Feb; 100():104955. PubMed ID: 38171113
[TBL] [Abstract] [Full Text] [Related]
8. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract] [Full Text] [Related]
9. Real-world relapse-free survival data on adjuvant anti-pd-1 therapy for patients with newly diagnosed and recurrent stage III melanoma.
Stahlie EHA; Zijlker LP; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
Melanoma Res; 2024 Feb; 34(1):63-69. PubMed ID: 38016153
[TBL] [Abstract] [Full Text] [Related]
10. H-Scan Discrimination for tumor Microenvironmental Heterogeneity in Melanoma.
Baek J; Qin SS; Prieto PA; Parker KJ
Ultrasound Med Biol; 2024 Feb; 50(2):268-276. PubMed ID: 37993356
[TBL] [Abstract] [Full Text] [Related]
11. Protein Disulfide Isomerase A2 Is Correlated with Immune Infiltrates and Is a Novel Prognostic Biomarker in Glioma Patients.
Ma ZG; Liu YX; Zou N; Huang Z; Wang M; Li T; Zhou J; Chen LG
Curr Med Sci; 2023 Dec; 43(6):1107-1115. PubMed ID: 37978154
[TBL] [Abstract] [Full Text] [Related]
12. Sustained improved survival of patients with metastatic melanoma after the introduction of anti-pd-1-based therapies.
Schina A; Pedersen S; Spenning AL; Laursen OK; Pedersen C; Haslund CA; Schmidt H; Bastholt L; Svane IM; Ellebaek E; Donia M
Eur J Cancer; 2023 Dec; 195():113392. PubMed ID: 37924648
[TBL] [Abstract] [Full Text] [Related]
13. Modern diagnostics and treatment of Merkel cell carcinoma.
Weilandt J; Peitsch WK
J Dtsch Dermatol Ges; 2023 Dec; 21(12):1524-1546. PubMed ID: 37875785
[TBL] [Abstract] [Full Text] [Related]
14.
Huang X; Chen L; Sha T; Lin Y; Zeng R; Xu J; Chen S; Cai HH; Zhang J; Zhou H; Sun PH; Jiang X
ACS Nano; 2023 Oct; 17(20):20073-20086. PubMed ID: 37792448
[TBL] [Abstract] [Full Text] [Related]
15. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract] [Full Text] [Related]
16. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract] [Full Text] [Related]
17. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Ascierto PA; Agarwala SS; Warner AB; Ernstoff MS; Fox BA; Gajewski TF; Galon J; Garbe C; Gastman BR; Gershenwald JE; Kalinski P; Krogsgaard M; Leidner RS; Lo RS; Menzies AM; Michielin O; Poulikakos PI; Weber JS; Caracò C; Osman I; Puzanov I; Thurin M
J Transl Med; 2023 Jul; 21(1):508. PubMed ID: 37507765
[TBL] [Abstract] [Full Text] [Related]
18. Prognosis in stage II melanoma of the head and neck depends on the histological subtype.
Jasper S; Keim U; Leiter U; Amaral T; Flatz L; Forschner A
J Dtsch Dermatol Ges; 2023 Oct; 21(10):1137-1146. PubMed ID: 37485634
[TBL] [Abstract] [Full Text] [Related]
19. Linear Peptide-Based PET Tracers for Imaging PD-L1 in tumors.
Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
[TBL] [Abstract] [Full Text] [Related]
20. Neurosarcomatous amelanotic transformation of malignant melanoma presenting as malignant periopheral nerve sheath tumor: Rare case report.
Bofan L; Xiaofei X; Jingwen Z; Zuzhuo Z; Tianxiao M; Feng G; Guochuan Z; Zhou Z
Medicine (Baltimore); 2023 Jun; 102(25):e34034. PubMed ID: 37352079
[TBL] [Abstract] [Full Text] [Related]
[Next]
